



# Fosun Newsletter

December 2014 – January 2015

## Stock Information

Stock Price (30/1/2015).....HKD 10.88  
 52-week range.....HKD 8.03-10.88  
 Total shares (mn shares).....6,922  
 Market Value (HKD bn).....75.31



## Highlight

### Fosun International to Acquire Meadowbrook Insurance Group, Inc.

On 30 December 2014 (U.S. time), Fosun International and Meadowbrook Insurance Group, Inc. ("Meadowbrook") announced that they entered into a merger agreement under which Fosun International will acquire Meadowbrook by way of merger, for US\$8.65 per share in cash, representing an aggregate transaction value of approximately US\$433 million. Following the closing of the transaction, which is expected in the second half of 2015, Meadowbrook will become an indirect wholly-owned subsidiary of Fosun International. Meadowbrook will continue to maintain its headquarters in Southfield, Michigan and operate under the Meadowbrook brand name. The acquisition of Meadowbrook will enable Fosun to establish a significant presence in the U.S. P&C market.

## Insurance

Gross Premium Written (thousand RMB)	Yong'an P&C Insurance	Pramerica Fosun Life Insurance
December 2014	597,452.2	4,660.8
Jan - Dec 2014	6,993,680.7	41,730.4

Note: Peak Re and Fosun Insurance Portugal don't announce their monthly gross premium written.

## Industrial Operations

### Fosun Pharma

#### Fosun Pharma Releases "2020 Innovation Program" on its 20th Anniversary

On 27 December 2014, Fosun Pharma celebrated its 20th Anniversary. During the ceremony, Fosun Pharma released its 2020 Innovation Program for innovation and R&D. According to the program, in the next five years, Fosun Pharma will establish a Shanghai-based global innovation and R&D system, striving to become a pharmaceutical enterprise with globalized innovation and R&D capabilities. During the ceremony, Fosun Pharma conducted the opening ceremony of "Fosun Science Park" and the launching ceremony of "Fosun Pharma-Shanghai Henlius Biotech Industrialization Base". The production base, with a planned GFA of 10,000+ square meters, is designed and renovated in line with GMP standards as required in China, Europe and the U.S., and also adopts the internationally advanced one-time production technology.

#### Fosun Pharma's Artesunate is Added to the Honors List of the French Medical Journal Prescrire

On 29 January 2015, Artesunate for injection, the medicinal product for severe malaria treatment from Fosun Pharmaceutical was included in the Honours List 2014 of the Prescrire, an independent French medical journal, becoming the first Chinese innovative drug on the list. The Prescrire Annual Drug Awards are famous for its absolute independent and stringent criteria in the healthcare industry. Its selections are highly recognized by healthcare professionals, and it is honored as the Oscar of pharmaceutical industry. Its HONORS LIST includes the medicines of a clear advantage compared with the existing therapeutic options in their respective areas.

## Hainan Mining

On 9 December 2014, Hainan Mining was listed on the Shanghai Stock Exchange with stock code 601969. Hainan Mining issued 186,670,000 shares at a price of RMB10.34 per share. Following the completion of the A Share IPO, Fosun International's equity interest (through Shanghai Fosun High Technology (Group) Co. Ltd. and Shanghai Fosun Industrial Investment Co., Ltd.) in Hainan Mining has been diluted from 60% to 54%. Hainan Mining remains as our subsidiary.

## Forte

	Attributable Sales GFA (sq.m.)	Attributable Sales Amount (RMB mn)
December 2014	191,192	2,370
Jan- Dec 2014	<b>947,672</b>	<b>13,274</b>
January 2015	42,307	516

# Investment

## Fosun Property finishes its 2nd property acquisition in Tokyo

On 1 December 2014, IDERA Capital Management Ltd. ("IDERA") under Fosun Property announced the acquisition of a large-sized office building located in Shinagawa Seaside, Shinagawa-ku, Tokyo, namely "Shinagawa Seaside Park Tower". It is the second property investment for Fosun Property in 2014, following the acquisition of "SeaFort Square Citi Group Center Building" in August. IDERA will be appointed as the asset manager for the acquired asset.

IDERA is a leading fund management and asset management company in Japan. In May 2014, IDERA became a subsidiary of Fosun and acquired Citi Group Center in Tokyo three months later. Now the second deal is finalized quickly, which well demonstrates its ability in property investment in Japan.


## Fosun Pharmacy to Acquire Erye Pharma for RMB451 Million

On 4 December 2014, Fosun Pharmacy announced to acquire 65% equity interest in Suzhou Erye Pharmaceutical Limited (Erye Pharmaceutical), and may acquire the left 35% equity interest of Erye Pharmaceutical for no more than RMB682.5 Million in the future deal. The acquisition will reform anti-infective drug platform for Fosun Pharma, and further strengthen its core competitiveness in Pharmaceuticals industry.

## Fosun Property Announces the Acquisition of a North Sydney Office Building

Fosun Property has partnered with Propertylink to acquire the 73 Miller Street office property in North Sydney on 26 January 2015. 73 Miller Street will become a part of the property portfolio held by Fosun's insurance arm. The A-grade commercial tower features 14,672 sqm of gross leasable area in the core district of the 'golden triangle' with outstanding access to public transport, 156 car spaces and views of Sydney Harbour. The property is 100% leased with the NSW Government as an anchor tenant. The building is given a 4.5 star NABERS rating (out of a maximum 5 star).

Propertylink is a leading real estate and infrastructure investment manager in Australia, with more than AUD \$2 billion in asset under management and over AUD \$700 million of assets acquired throughout 2014.

**The Group<sup>(1)</sup>**


- Except where otherwise noted, shareholding held percentages represent effective equity interests as at 30 June 2014.
- The Group held the equity interests in Yong'an P&C Insurance through the subsidiaries, Shanghai Fosun Industrial Technology Development Co., Ltd. ("Fosun Industrial Development") and Shanghai Fosun Industrial Investment Co., Ltd. ("Fosun Industrial Investment"), as to 16.18% and 3.75% respectively.
- On 9 December 2015, Hainan Mining was listed on the Shanghai Stock Exchange. Following the completion of the IPO, the Group's equity interest in Hainan Mining has been diluted from 60% to 54%.
- The Group held 3.6% equity interests in Zhaojin Mining via its subsidiary Fosun Industrial Investment. As Yuyuan, 29.91% owned associate of the Group, also held 25.69% equity interests in Zhaojin Mining, the Group held totally 11.25% effective equity interests in Zhaojin Mining.
- The Group held 17.41% shares of Giovanna Group Holdings Limited while Giovanna Group Holdings Limited indirectly wholly owns Focus Media.
- The Group held 9.96% equity interests in Folli Follie. In addition, Prameria-Fosun China Opportunity Fund held 3.89% equity interests through its wholly-owned subsidiary.
- The Group held its A shares through its subsidiary, Nanjing Iron & Steel, and its wholly-owned subsidiary, Fosun Industrial Development, representing 0.66% and 0.35% of its total number of A shares respectively; the Company and its wholly-owned subsidiary Topper Link Limited held its H shares representing 9.15% of its total number of H shares. In addition, Prameria-Fosun Opportunity Fund held its H shares representing 0.51% of its total number of H shares.
- The names of the Group's investment projects.
- The Group directly held 50% equity interests while the other 50% were held by Star Capital. As a result the Group held its effective equity interests of 64%.
- Shanghai Star Capital Investment Management Co., Ltd., general partner ("GP") of Star Capital.
- Tibet Fosun Investment Management Co., Ltd., GP of Fosun Chuanghong.
- Shanghai Fosun Capital Investment Management Co., Ltd., GP of Fosun Capital.
- Carlyle-Fosun (Shanghai) Equity Investment Management Co., Ltd., GP of Carlyle-Fosun.
- Fosun Equity Investment Ltd., GP of Prameria-Fosun China Opportunity Fund.

## Contact Us

Fosun International Investor Relations Department  
 E-mail: [IR@fosun.com](mailto:IR@fosun.com)  
 Address: No.2, East Fuxing Rd, Shanghai

### Disclaimer

This document herewith includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited and its portfolio companies expect or anticipate will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risk and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.